Cargando…
Half-dose ocrelizumab in selected patients with relapsing–remitting multiple sclerosis
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257484/ https://www.ncbi.nlm.nih.gov/pubmed/37301802 http://dx.doi.org/10.1007/s13760-023-02303-0 |
| _version_ | 1785057311912361984 |
|---|---|
| author | Algahtani, Hussein Shirah, Bader Alqahtani, Abdulhadi Abdelghaffar, Nawal Makki, Samiah |
| author_facet | Algahtani, Hussein Shirah, Bader Alqahtani, Abdulhadi Abdelghaffar, Nawal Makki, Samiah |
| author_sort | Algahtani, Hussein |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10257484 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-102574842023-06-12 Half-dose ocrelizumab in selected patients with relapsing–remitting multiple sclerosis Algahtani, Hussein Shirah, Bader Alqahtani, Abdulhadi Abdelghaffar, Nawal Makki, Samiah Acta Neurol Belg Letter to the Editor Springer International Publishing 2023-06-10 /pmc/articles/PMC10257484/ /pubmed/37301802 http://dx.doi.org/10.1007/s13760-023-02303-0 Text en © The Author(s) under exclusive licence to Belgian Neurological Society 2023 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Letter to the Editor Algahtani, Hussein Shirah, Bader Alqahtani, Abdulhadi Abdelghaffar, Nawal Makki, Samiah Half-dose ocrelizumab in selected patients with relapsing–remitting multiple sclerosis |
| title | Half-dose ocrelizumab in selected patients with relapsing–remitting multiple sclerosis |
| title_full | Half-dose ocrelizumab in selected patients with relapsing–remitting multiple sclerosis |
| title_fullStr | Half-dose ocrelizumab in selected patients with relapsing–remitting multiple sclerosis |
| title_full_unstemmed | Half-dose ocrelizumab in selected patients with relapsing–remitting multiple sclerosis |
| title_short | Half-dose ocrelizumab in selected patients with relapsing–remitting multiple sclerosis |
| title_sort | half-dose ocrelizumab in selected patients with relapsing–remitting multiple sclerosis |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257484/ https://www.ncbi.nlm.nih.gov/pubmed/37301802 http://dx.doi.org/10.1007/s13760-023-02303-0 |
| work_keys_str_mv | AT algahtanihussein halfdoseocrelizumabinselectedpatientswithrelapsingremittingmultiplesclerosis AT shirahbader halfdoseocrelizumabinselectedpatientswithrelapsingremittingmultiplesclerosis AT alqahtaniabdulhadi halfdoseocrelizumabinselectedpatientswithrelapsingremittingmultiplesclerosis AT abdelghaffarnawal halfdoseocrelizumabinselectedpatientswithrelapsingremittingmultiplesclerosis AT makkisamiah halfdoseocrelizumabinselectedpatientswithrelapsingremittingmultiplesclerosis |